Induction of anti-proliferative and apoptotic effects by anti-IL-25 receptor single chain antibodies in breast cancer cells

International Immunopharmacology

Volumn 23, Issue 2, 2014, Pages 624-632

  Younesi, Vahid ^a   Nejatollahi, Foroogh ^a,b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti IL25 receptor scFv; Breast cancer; Interleukin 25; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; INTERLEUKIN 25; INTERLEUKIN 25 RECEPTOR SINGLE CHAIN ANTIBODY; LIPOCORTIN 5; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; IL-25 RECEPTOR PROTEIN, HUMAN; INTERLEUKIN RECEPTOR; PROTEIN BINDING;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BURKITT LYMPHOMA; CANCER CELL; CANCER IMMUNOTHERAPY; CASPASE ASSAY; CELL COUNT; CELL DEATH; CELL GROWTH; CELL POPULATION; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MTT ASSAY; RAJI CELL LINE; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; IMMUNOLOGY; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; MCF-7 CELLS; PROTEIN BINDING; RECEPTORS, INTERLEUKIN; SINGLE-CHAIN ANTIBODIES;

EID: 84913533385     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2014.10.015     Document Type: Article

References (32)

1. Lee J, Ho WH, Maruoka M, Corpuz RT, Baldwin DT, Foster JS, et al. IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J Biol Chem 2001;276:1660-4.
2. Letuve S, Lajoie-Kadoch S, Audusseau S, Rothenberg ME, Fiset PO, Ludwig MS, et al. IL-17E upregulates the expression of proinflammatory cytokines in lung fibroblasts. J Allergy Clin Immunol 2006;117:590-6.
3. Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003;14:155-74.
4. Monteleone G, Pallone F, Macdonald TT. Interleukin-25: a two-edged sword in the control of immune-inflammatory responses. Cytokine Growth Factor Rev 2010;21:471-5.
5. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009;9:556-67.
6. Tian E, Sawyer JR, Largaespada DA, Jenkins NA, Copeland NG, Shaughnessy Jr JD. Evi27 encodes a novel membrane protein with homology to the IL17 receptor. Oncogene 2000;19:2098-109.
7. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011;34:149-62.
8. Maezawa Y, Nakajima H, Suzuki K, Tamachi T, Ikeda K, Inoue J, et al. Involvement of TNF receptor-associated factor 6 in IL-25 receptor signaling. J Immunol 2006;176:1013-8.
9. Furuta S, Jeng YM, Zhou L, Huang L, Kuhn I, Bissell MJ, et al. IL-25 causes apoptosis of IL-25R-expressing breast cancer cells without toxicity to nonmalignant cells. Sci Transl Med 2011;3:78ra31.
10. Furuta S, Jiang X, Gu B, Cheng E, Chen PL, Lee WH. Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proc Natl Acad Sci U S A 2005;102:9176-81.
11. Huang CK, Yang CY, Jeng YM, Chen CL, Wu HH, Chang YC. Autocrine/paracrine mechanism of interleukin-17B receptor promotes breast tumorigenesis through NF-kappaB-mediated antiapoptotic pathway. Oncogene 2013;33:2968-77.
12. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4:11-22.
13. Yan L, Davis HM. Pharmacogenetics and pharmacogenomics of therapeutic monoclonal antibodies. Pharmacogenomics 2006;7:961-4.
14. Kontermann RE. Antibody-cytokine fusion proteins. Arch Biochem Biophys 2012;526:194-205.
15. Pasche N, Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 2012;17:583-90.
16. Reichert JM. Trends in the development of therapeutic anti-cytokine antibodies. Drug Discov Today 2004;9:348.
17. Zagury D, Gallo RC. Anti-cytokine Ab immune therapy: present status and perspectives. Drug Discov Today 2004;9:72-81.
18. Schirrmann T, Meyer T, Schutte M, Frenzel A, Hust M. Phage display for the generation of antibodies for proteome research, diagnostics and therapy. Molecules 2011;16:412-26.
19. Thie H, Meyer T, Schirrmann T, Hust M, Dubel S. Phage display derived therapeutic antibodies. Curr Pharm Biotechnol 2008;9:439-46.
20. Hagemeyer CE, von Zur Muhlen C, von Elverfeldt D, Peter K. Single-chain antibodies as diagnostic tools and therapeutic agents. Thromb Haemost 2009;101:1012-9.
21. Accardi L, Di Bonito P. Antibodies in single-chain format against tumour-associated antigens: present and future applications. Curr Med Chem 2010;17:1730-55.
22. Nejatollahi F, Hodgetts SJ, Vallely PJ, Burnie JP. Neutralising human recombinant antibodies to human cytomegalovirus glycoproteins gB and gH. FEMS Immunol Med Microbiol 2002;34:237-44.
23. Nejatollahi F, Malek-Hosseini Z, Mehrabani D. Development of single chain antibodies to P185 tumor antigen. Iran Red Crescent Med J 2008;10:298-302.
24. Nejatollahi F, Abdi S, Asgharpour M. Antiproliferative and apoptotic effects of a specific antiprostate stem cell single chain antibody on human prostate cancer cells. J Oncol 2013;2013:839831.
25. Sommaruga S, Lombardi A, Salvade A, Mazzucchelli S, Corsi F, Galeffi P, et al. Highly efficient production of anti-HER2 scFv antibody variant for targeting breast cancer cells. Appl Microbiol Biotechnol 2011;91:613-21.
26. Gupta P, Han SY, Holgado-Madruga M, Mitra SS, Li G, Nitta RT, et al. Development of an EGFRvIII specific recombinant antibody. BMC Biotechnol 2010;10:72.
27. Albrecht H, Denardo GL, Denardo SJ. Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers. Q J Nucl Med Mol Imaging 2007;51:304-13.
28. Thathaisong U, Maneewatch S, Kulkeaw K, Thueng-In K, Poungpair O, P S. Human monoclonal single chain anti-bodies (HuScFv) that bind to the poly-merase proteins of influenza A virus. Asian Pac J Allergy Immunol 2010;26:23-35.
29. Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, et al. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer 2010;4:35-41.
30. Benatar T, Cao MY, Lee Y, Lightfoot J, Feng N, Gu X, et al. IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo. Cancer Immunol Immunother 2010;59:805-17.
31. Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol 2002;71:1-8.
32. Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol 2012;2:62.